Market Access A step forward, but not the finish line: What NICE’s QALY up... Healthcare in the UK is at an inflection point.
Market Access Beyond the Bill: how do we make medicines affordable without... Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.
Market Access NICE contribution to the cost per QALY threshold debate? Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c
Views & Analysis Collaboration can ensure access to life-changing innovation As a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new care infrastructure.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
